Asuragen to Present at the 2019 American Society of Human Genetics (ASHG) Annual Meeting

October 8, 2019 |

2 min read

Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, will highlight its rapidly growing AmplideX product portfolio and its novel data analysis software applications for challenging repetitive sequences at the upcoming American Society of Human Genetics (ASHG) Annual Meeting in Houston, Texas on October 15-19.

AUSTIN, Texas--(BUSINESS WIRE)-- Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, will highlight its rapidly growing AmplideX product portfolio and its novel data analysis software applications for challenging repetitive sequences at the upcoming American Society of Human Genetics (ASHG) Annual Meeting in Houston, Texas on October 15-19. Asuragen and its collaborators will be showcasing the robust performance of the AmplideX portfolio of assays and the company’s artificial intelligence-informed software developments as part of the conference’s scientific poster sessions.

The first of these poster presentations, reviewing the development of a convolutional neural network to accurately detect and interpret repetitive DNA sequences, will occur on Thursday, October 17from 2-3pm in the Bioinformatics and Computational Approaches section.

1477T: A deep learning framework for interpreting repetitive DNA sequence in heritable disease (Jessica Larson, PhD, Asuragen)

Two additional posters from Asuragen’s collaborators, highlighting the performance and robustness of the assays in their practices, will be presented in the Molecular and Cytogenetic Diagnostics section on Thursday, October 17 from 3-4pm and Friday, October 18 from 1-3pm, respectively.

2488T: FMR1 methylation and sizing PCR assays improve sensitivity and efficiency in clinical testing for fragile X syndrome, revealing some uncommon and unexpected results. (Jennifer Lee, PhD, Greenwood Genetic Center)

2564F: Clinical validation and implementation of a highly efficient and sensitive dual molecular diagnostic assay for myotonic dystrophy type 1. (Joseph Alaimo, PhD, Kansas City Children’s Mercy Hospital)

“Our AmplideX portfolio of products provide our customers reliable and streamlined solutions for the analysis of challenging genomic targets,” said Matthew McManus, MD, PhD, president and CEO of Asuragen. “The 2019 ASHG Annual Meeting is a great opportunity to showcase our latest developments and product pipeline with the broader genetics community and to align with molecular laboratories to ensure our pipeline addresses their needs and challenges.”

The company will also have a presence at booth #518 during the conference.

About Asuragen

Asuragen is a molecular diagnostic product company changing the way patients are treated in genetics and oncology. Asuragen’s diagnostic systems, composed of proprietary chemistry and software, deliver powerful answers using broadly installed instrument platforms. They are simple to adopt and expand the ability to serve patients. Asuragen is a product foundry rapidly and efficiently addressing current and emerging clinical needs, including cancer diagnosis and monitoring, reproductive health and aging, serving laboratories across a patient’s lifespan with its best in class diagnostic tests. For more information, visit www.asuragen.com.